Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

pies in the class of oncolytic immunotherapies," stated David H. Kirn, M.D., founder, chief medical officer and president of R&D of Jennerex.  "In the Phase 2 trial presented at ILCA, JX-594 demonstrated its ability to selectively target and destroy tumors following intravenous infusion. This finding confirms the ability of JX-594 to target both primary and metastatic, or distant, tumors which we believe is important in this HCC patient population and most cancers."

"We have treated more than 160 patients with JX-594 to date and are actively enrolling a multinational Phase 2b study in second line treatment of liver cancer patients, a Phase 2 all-IV trial in first line HCC patients, and a Phase 2 study in colorectal cancer.  The data presented today build on the growing body of promising clinical data showing that JX-594 has a direct anti-tumor effect and can stimulate an immune response killing cancer cells," stated Laurent Fischer, M.D., president and chief executive officer of Jennerex. "We are excited with the progress we are making in our JX-594 program and believe it has the potential to advance patient care across multiple types of cancer."

The abstract (#2012-1304) entitled "Phase 2 Trial Of JX-594, A Targeted Multi-Mechanistic Oncolytic Vaccinia Virus, Followed By Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)" was presented at the International Liver Cancer Association Annual Meeting in Berlin.

About this Trial:

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intratumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

Following treatment with JX-594 alone at four weeks, 62 percent of patients had disease control as measured by modified RECIST (tumor burden measurement). 
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ATLANTA , June 29, 2015  Alimera Sciences, ... that specializes in the research, development and commercialization of ... , Chief Operating Officer and Chief Financial Officer, will ... on July 8, 2015 at 8:00 a.m. ET at ... . The presentation will be webcast ...
(Date:6/29/2015)... , June 29, 2015 Regeneron ... that the Proceedings of the National Academy ... demonstrating that the Company,s proprietary VelociGene ® ... identification and preclinical validation of potential candidates that ... of Middle East Respiratory Syndrome (MERS). This involved ...
(Date:6/29/2015)... June 29, 2015  Arbor Solution has added ... The high-powered, multi-functional M2150 offers two ... Haswell Core i5-4402E 1.6 GHz processor and ... processing and computing performance. Integrated Intel® HD Graphics ... well suited for graphics-intense applications in operating rooms, ...
Breaking Medicine Technology:Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 2Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 4Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 5Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... TURKU, Finland, July 3 BioCis ... headquarters in Turku, Finland,announced positive results from its Phase ... topical drug for dermatology. This,double-blind, placebo-controlled study, conducted in ... who applied the ProtoCure,emulsion cream to the affected skin ...
... Tenn., July 2 Acura Pharmaceuticals, Inc. (Nasdaq: ... ) announced today that the U.S. Food and Drug Administration ... Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, ... relief of moderate-to-severe pain. , , (Logo: ...
Cached Medicine Technology:BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 2Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 2Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 3
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... that Ellen D. Wagner, Chief Research and Strategy Officer at Predictive Analytics Reporting ... at the National Science Foundation (NSF), will provide keynote addresses at the 2015 ...
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up to 80% of the ... range from a dull, constant ache (chronic) to a sudden sharp pain (acute). In ... selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & Regenerative Medicine now ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... after a 5-day tour in India. During her stay, she met with ... Trivedi Master Wellness™ and Transformational Leader/Internationally Beloved Spiritual Master Mahendra Trivedi to ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... bright skies and inspirational words. , The independent, coeducational, special needs boarding ... Glenholme building to the school’s Center for the Arts. Along the way, the ...
(Date:6/30/2015)... New York, NY (PRWEB) , ... June 30, ... ... and students are critical in order to enhance successful student outcomes. According ... on the teacher’s capacity to adapt.” Teachers must be able to show “all ...
Breaking Medicine News(10 mins):Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3Health News:The Glenholme School Graduates Its Class of 2015 2Health News:The Glenholme School Graduates Its Class of 2015 3Health News:The Glenholme School Graduates Its Class of 2015 4Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2
... be further explored, researchers say , TUESDAY, Nov. 17 ... likely to die after admission to the hospital with ... suggests. , "After admission to a hospital, trauma ... the study authors wrote. "This concerning finding warrants more ...
... show need for improvement , TUESDAY, Nov. 17 (HealthDay ... job of reducing preterm births, according to a new ... high numbers of early, life-threatening deliveries. , , Vermont ... preterm birth rate under 10 percent, while in Louisiana, ...
... BEACH, Calif., Nov. 17 With these tough economic times, ... gifting this year. Imagine being able to donate to ... and overworked feet. Yoga Sandals® Footwear by Beech Sandal ... feet flexible with 20% of each purchase donated to a ...
... ... working is emerging as the top business objective for employer-sponsored wellness programs around the ... New ... is emerging as the top business objective for employer-sponsored wellness programs around ...
... XOWii is continuing ... was launched in early October, has met with much success. XOWii Thin is looking to ... healthy weight control. , ... November 16, 2009 --The XOWii company has made it their vision to be at the ...
... ... a total settlement of $3.25 million for two sanitation workers whose garbage truck was hit by ... Barnes lawyer Michael Cooper. , ... (Lexis Nexis) November 17, 2009 -- New York law firm Cellino & Barnes ...
Cached Medicine News:Health News:Uninsured Trauma Patients More Likely to Die: Study 2Health News:U.S. Scores a 'D' on Preterm Birth Report Card 2Health News:U.S. Scores a 'D' on Preterm Birth Report Card 3Health News:U.S. Scores a 'D' on Preterm Birth Report Card 4Health News:Give a Gift that Gives Back With Yoga Sandals(R) Comfys 2Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 2Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 3Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 4Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 5Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 6Health News:XOWii Launches Second Product in its Line of What are Proving to be Impeccably Designed and Unique Products 2Health News:New York Personal Injury Law Firm Cellino & Barnes Wins $3.25 Million Settlement For Workers Injured in Truck Accident 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: